There are various methods by which we can treat multivessel CAD in diabetic patients. Although conventional bypass (cCABG) is more beneficial than percutaneous coronary intervention (PCI) with drug eluting stents (DES) for myocardial revascularization in diabetics with multivessel CAD, diabetics are also the patients who experience the most complications, infections, and highest costs with cCABG through a sternotomy. Recently, we developed and diffused MICS CABG, which can be combined with PCI/DES to vessels other than the one at the front of the heart in order to constitute hybrid coronary revascularization (HCR). The safety and efficacy of MICS CABG was recently validated in a multicentre study from our research team, with 100% patency of the left internal thoracic artery (LITA)-LAD axis on angiography7. Potential advantages of an HCR approach in diabetics include the avoidance of a sternotomy and the potential for earlier recovery, less bleeding and transfusions, fewer infections, decreased costs, increased patient acceptance, while potentially maintaining the benefits of cCABG due to the LITA-LAD axis in a diabetic population.